Effectiveness of a simply designed tumor vaccine in prevention of malignant melanoma development

Japanese Journal of Cancer Research

Volumn 90, Issue 10, 1999, Pages 1130-1138

  Novaković, Srdjan ^a   Ihan, Alojz ^b   Jezeršek, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cancer; Melanoma; Prevention; Tumor vaccine

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; PYRAN COPOLYMER; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; MACROPHAGE FUNCTION; MELANOMA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TIME; TUMOR IMMUNITY;

EID: 0032729427     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00687.x     Document Type: Article

References (39)

1. Oettgen, H. and Old, L. J. The history of cancer immunotherapy. In "Biologic Therapy of Cancer," ed. V. T. De Vita, S. Hellman and S. A. Rosenberg, pp. 53-66 (1991). Lippincott, Philadelphia.
2. Novaković, S., Menart, V., Gaberc-Porekar, V., Štalc, A., Serša, G., Čemažar, M. and Jezeršek, B. New TNF-α analogues: a powerful but less toxic biological tool against tumors. Cytokine, 8, 597-604 (1997).
3. Novaković, S. Current approaches to gene therapy in oncology: construction of tumor vaccines. Radial. Oncol., 30, 260-267 (1996).
4. Zwiebel, A. J., Su, N., MacPherson, A., Davis, T. and Ojeifo, O. J. The gene therapy of cancer: transgenic immunotherapy. Semin. Hematol., 30, 119-129 (1993).
5. Allione, A., Consalvo, M., Nanni, P., Lollini, L. P., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, P. M., Dellabona, P., Hock, H., Blankenstein, T., Rosenthal, M. F., Gansbacher, B., Bosco, C. M., Musso, T., Gusella, L. and Forni, G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res., 54, 6022-6026 (1994).
6. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, C. R. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90, 3539-3543 (1993).
7. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R. and Gilboa, E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172, 1217-1224 (1990).
8. Russell, S. J., Eccles, S. A., Flemming, C. L., Johnson, C. A. and Collins, M. K. L. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer, 47, 244-251 (1991).
9. Plaksin, D., Porgador, A., Vadai, E., Feldman, M., Schirrmacher, V. and Eisenbach, L. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int. J. Cancer, 59, 796-801 (1994).
10. Townsend, S. E. and Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259, 368-370 (1993).
11. Townsend, S. E., Su, F. W., Atherton, J. M. and Allison, J. P. Specificity and longevity of antitumor immune response induced by B7-transfected tumors. Cancer Res., 54, 6477-6483 (1994).
12. Drazan, E. K., Shen, D. X., Csete, E. M., Zhang, W. W., Roth, A. J., Busuttil, W. R. and Shaked, A. In vivo adeno-viral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery, 116, 197-204 (1994).
13. Roth, A. J., Mukhopadhyay, T., Zhang, W. W., Fujiwara, T. and Georges, R. Gene replacement strategies for the prevention and therapy of cancer. In "The Internet Book of Gene Therapy/Cancer Therapeutics," ed. E. R. Sobol and J. K. Scanlon, pp. 229-233 (1995). Appleton & Lange, Stamford.
14. Moolten, F. L. and Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst., 82, 297-300 (1990).
15. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1, 279-287 (1994).
16. Sobol, E. R. and Scanlon, J. K. "The Internet Book of Gene Therapy/Cancer Therapeutics" (1995). Appleton & Lange, Stamford.
17. Budzynski, W., Chirigos, M. and Gruys, E. Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Immunol. Immunother., 24, 253-258 (1987).
18. Salup, R. R., Herberman, R. B., Chirigos, M. A., Back, T. and Wiltrout, R. H. Therapy of peritoneal murine cancer with biological response modifiers. J. Immunopharmacol., 7, 417-436 (1985).
19. Wallace, P. K. and Morahan, P. S. Role of macrophages in the immunotherapy of Lewis lung peritoneal carcinomatosis. J. Leukoc. Biol., 56, 41-51 (1994).
20. Belardelli, F., Gresser, I., Maury, C. and Maunoury, M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int. J. Cancer, 30, 821-825 (1982).
21. Hock, H., Dorsch, M., Kunzendorf, U., Quin, Z., Diamantstein, T. and Blankenstein, T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res., 53, 1-3 (1993).
22. Scaringi, L., Tissi, L., Cornacchione, P., Rosati, E., Campanelli, C., von Hunolstein, C., Orefici, G., Rossi, R. and Marconi, P. Antibody-independent protection in mice against type Ia group B streptococcus lethal infection. FEMS Immunol. Med. Microbiol., 9, 151-162 (1994).
23. Morahan, P. S., Pinto, A., Stewart, D., Murasco, D. M. and Brinton, M. A. Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forrest virus infection. Antiviral Res., 15, 241-254 (1991).
24. Piccoli, M., Saito, T. and Chirigos, M. A. Bimodal effects of MVE-2 on cytotoxic activity of natural killer cell and macrophage tumoricidal activities. Int. J. Immunopharmacol., 6, 569-576 (1984).
25. Rios, A., Rosenblum, M., Powell, M. and Hersh, E. Phase I study of MVE-2 therapy in human cancer. Cancer Treat. Rep., 67, 239-243 (1983).
26. Shlick, E., Ruffmann, R., Hartung, K. and Chirigos, M. A. Modulation of myelopoiesis by CSF or CSF-inducing biological response modifiers. J. Immunopharmacol., 7, 141-166 (1985).
27. Kaneda, Y., Yamamoto, Y., Tsunoda, S., Kamida, H., Tsutsumi, Y., Hirano, T. and Mayumi, T. Bioconjugation of tumor necrosis factor-alpha with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency. Biochem. Biophys. Res. Commun., 239, 160-165 (1997).
28. Yamamoto, H., Miki, T., Oda, T., Hirano, T., Sera, Y., Akagi, M. and Maeda, H. Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ethermaleic acid copolymer. Eur. J. Cancer, 26, 253-260 (1990).
29. Blankenstein, T., Qin, Z., Überla, K., Müller, W., Rosen, H., Volk, H. D. and Diamantstein, T. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med., 173, 1047-1052 (1991).
30. Schirrmacher, V. Biotherapy of cancer/perspectives of immunotherapy and gene therapy. J. Cancer Res. Clin. Oncol., 121, 443-451 (1995).
31. Guo, Y. J., Che, X. Y., Shen, F., Ma, J., Wang, X. N., Wu, S. G., Anthony, D. D. and Wu, C. M. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat. Med., 3, 451-455 (1997).
32. Sampson, H. J., Archer, E. G., Ashley, M. D., Fuchs, E. H., Hale, P. L., Dranoff, G. and Bigner, D. D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA, 93, 10399-10404 (1996).
33. Borden, E. C. and Sondel, P. M. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer, 65, 800-814 (1990).
34. Kelso, A. Cytokines: structure function and synthesis. Curr. Opin. Immunol., 2, 215-225 (1989).
35. Rosenberg, S. A., Lotze, M. T. and Mule, J. J. New approaches to the immunotherapy of cancer. Ann. Intern. Med., 108, 853-864 (1988).
36. Ehrke, M. J., Verstovšek, S., Krawczyk, M. C., Ujházy, P., Zaleskis, G., Maccubin, L. D. and Mihich, E. Cyclophosphamide plus tumor necrosis factor-α chemoimmunotherapy cured mice: life-long immunity and rejection of reimplanted primary lymphoma. Int. J. Cancer, 63, 463-471 (1995).
37. Bannerji, R., Arroyo, C. D., Cordon-Cardo, C. and Gilboa, E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol., 152, 2324-2332 (1994).
38. Bevan, M. J. Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med., 182, 639-641 (1995).
39. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 961-965 (1994).